Procter & Gamble Health Ltd.

₹5,503.5

69 (1.3%)

PGHL Share Price

Pharmaceuticals & Biotechnology

As on September 18, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 8,79,043 Cr

P/E Ratio27.95

Dividend Yield0.37 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	5,443.5	Bullish
10-DMA	5,504.8	Bearish
20-DMA	5,635.65	Bearish
50-DMA	6,111.08	Bearish
100-DMA	5,993.35	Bearish
200-DMA	5,631.29	Bearish

Historical Performance

1 Year

-12.2%

3 Years

11.8%

5 Years

1.9%

10 Years

655.2%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Compounded Sales Growth

10 Years:7.2

5 Years:6.9

3 Years:2.7

TTM:8.6

Compounded Profit Growth

10 Years:32.8

5 Years:13.1

3 Years:7.3

TTM:6.9

Stock Price CAGR

10 Years:22.5

5 Years:0.5

3 Years:3.7

TTM:-13.6

Return on Equity

10 Years:47.7

5 Years:116

3 Years:121.1

last year:196.9

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 27.95, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of 3.7%, indicating poor shareholder returns.
The stock carries a low beta of 0.5, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹4740 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹14080 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 880419.1

No. of Shares: 160 (Approx)

Performance:-12%

-119580.9

NIFTY Performance: -7.8%

1 day Top Gainers